Answers are grounded in this paper and cite their sources.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a long preclinical phase, making early biomarker discovery essential for timely diagnosis, risk stratification, and intervention. Hearing loss has increasingly been recognized as a clinically important and potentially modifiable factor associated with cognitive decline and dementia risk. Beyond peripheral auditory impairment, accumulating evidence suggests that central auditory dysfunction, altered auditory processing, and electrophysiological abnormalities may emerge during the course of AD and related cognitive disorders. Auditory electrophysiological signals, including electroencephalography (EEG), auditory event-related potentials (ERP), auditory evoked cortical potentials (AECP), auditory brainstem response (ABR) recordings, cochlear microphonics (CM), and distortion product otoacoustic emission (DPOAE) measures, provide objective and repeatable measurements of peripheral and central auditory pathway function. However, conventional analysis based on peak latency, amplitude, spectral power, and manually engineered features may not fully capture subtle disease-related alterations distributed across time, frequency, and waveform morphology. Artificial intelligence (AI) offers new opportunities to extract high-dimensional and physiologically informative representations from auditory and neural signals. Machine learning (ML), deep learning (DL), self-supervised learning (SSL), explainable artificial intelligence (XAI), and multimodal modeling can support data-driven biomarker discovery, especially in settings where labeled datasets are limited and electrophysiological changes are subtle. This critical narrative review synthesizes current knowledge at the intersection of hearing loss, AD, auditory electrophysiology, and AI. We discuss traditional signal processing, supervised ML, deep neural networks, self-supervised representation learning, explainable models, and multimodal integration strategies. We also identify major methodological limitations, including small sample sizes, heterogeneous acquisition protocols, insufficient external validation, limited interpretability, data leakage risks, and challenges in translating animal-model findings to human disease. Finally, we propose future directions for trustworthy, interpretable, and multimodal AI systems capable of advancing auditory electrophysiological biomarkers for AD and hearing-related neurodegeneration.
No takes yet. Share an insight, caveat, or question.
Iqbal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: